Wait for topline results on May 5 before taking a position. Positive data could expand aficamten's label significantly, while negative results would be a major setback.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $77.09entry
- T+1 · 7mo ago 0.00%α −1.38% · $77.09
- T+5 · 6mo ago −3.28%α −5.27% · $74.56
- T+20 · 6mo ago −8.02%α −12.97% · $70.91
- T+60 · 4mo ago +4.32%α +1.58% · $80.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cytokinetics announced it will report topline results from its ACACIA-HCM trial (aficamten in non-obstructive HCM) on May 5, 2026, with a conference call to follow. No results were disclosed in this press release.
Key Facts
- Topline results from Phase 3 ACACIA-HCM trial to be reported May 5, 2026
- Trial evaluates aficamten in patients with non-obstructive hypertrophic cardiomyopathy
- Conference call scheduled for 8:00 AM ET on May 5
Financial Impact
No financial data disclosed; impact depends on trial results
Risk Factors
- Trial may fail to meet primary endpoint
- Stock likely to be volatile around data release
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287103 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers